ASCO 2022: Advances in CLL/SLL

PCE

English - June 30, 2022 16:00 - 37 minutes - 34.2 MB - ★★★★ - 6 ratings
Courses Education Science Life Sciences app education np education podcasts for credit app medicine pa education np medicine pa medicine ce podcasts app podcasts cme podcasts Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: A Nursing Perspective on PARP Inhibitors in Prostate Cancer

Next Episode: Management of Atopic Dermatitis in Primary Care and Specialty Settings

In this episode, John M. Burke, MD, a leading expert, and Amy Esposito, FNP-C provide expert insights on key data presented at the 2022 ASCO annual conference for CLL/SLL regarding:

Updated response and safety results after 3 years of follow-up from the phase II CAPTIVATE study of ibrutinib and venetoclax in patients with previously untreated CLLUpdated response and remission rates after 4 years of follow-up from a phase II trial of obinutuzumab, ibrutinib, and venetoclax in patients with either treatment-naïve or relapsed/refractory CLLProgression free survival and safety results after 5 years of follow-up from the ELEVATE-TN phase III study of Acalabrutinib ± Obinutuzumab vs
Obinutuzumab + Chlorambucil as first-line therapy in CLLAssessments of whether racial and/or ethnic identity, and socioeconomic status are prognostic factors of survival in CLL

Presenter

John M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, Colorado

Moderator

Amy Esposito, FNP-C
Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado